Viacheslav G. Morozov
Research Subjects
Viacheslav G. Morozov has a total of 49 co-authors. Here are the top co-authors by number of shared publications:
- E. A. Kitsenko
Russian Scientific Center of Surgery named after academician B.V. Petrovsky
3 shared publications - Elena N. Bessonova
Ural State Medical University; Sverdlovsk Regional Clinical Hospital No. 1
3 shared publications - Marina Maevskaya
I.M. Sechenov First Moscow State Medical University (Sechenov University)
3 shared publications - Natalia Geyvandova
Stavropol Regional Hospital, Stavropol, Russian Federation
3 shared publications - Yu.V. Khoronko
Rostov State Medical University
3 shared publications Ю. В. Хоронько
ФГБОУ ВО «Ростовский государственный медицинский университет» Министерства здравоохранения Российской Федерации
3 shared publications
Latest Publications
- 3 October 2025
- Published by Media Sphere Publishing Group in Russian Journal of Evidence-Based Gastroenterology
- Vol. 14 (3)
Combination of ursodeoxycholic acid and glycyrrhizic acid (Phosphogliv URSO) in the treatment of nonalcoholic fatty liver disease: results of a multicenter randomized clinical trial on efficacy and safety
The use of an original combination of ursodeoxycholic acid (UDCA) and glycyrrhizic acid (GA) as a component of pathogenetic therapy may enhance the effectiveness of treatment for nonalcoholic fatty liver disease (NAFLD) due to their complementary effects. Objective. To evaluate the efficacy, tolerability, and safety of a 12-week therapy for NAFLD with Phosphogliv URSO (capsules containing UDCA 250 mg and GA 35 mg) in comparison with UDCA monotherapy (Ursophalk, capsules 250 mg) and Phosphogliv (capsules containing phospholipids 65 mg and GA 35 mg). Material and methods. In a randomized, multicenter, comparative, open-label trial (n=225), the efficacy and safety of Phosphogliv URSO were assessed in patients with NAFLD over 12 weeks, compared with UDCA monotherapy and Phosphogliv. The primary endpoint was the change in aminotransferase level — alanine aminotransferase (ALT) and aspartate aminotransferase (AST). Results. The hypothesis of superiority of the UDCA+GA combination with respect to the primary endpoint was confirmed in the Phosphogliv URSO group (n=75). More than a twofold reduction in ALT and AST levels was achieved (to 37.6±20.5 U/L and 31.5±16.7 U/L, respectively), exceeding the reductions in the UDCA group by 57% for ALT and 78% for AST (p0.4), with the lowest incidence observed in the Phosphogliv group (p<0.05). Conclusion. GA, through its anti-inflammatory, antioxidant, and antifibrotic properties, enhances the therapeutic effect of UDCA. The synergistic action of GA in combination with UDCA or phospholipids on key pathogenetic mechanisms of NAFLD suggests that these regimens may represent a promising alternative to UDCA monotherapy.
- 3 October 2025
- Published by Media Sphere Publishing Group in Russian Journal of Evidence-Based Gastroenterology
- Vol. 14 (3)
Combination of ursodeoxycholic acid and glycyrrhizic acid (Phosphogliv URSO) in the treatment of nonalcoholic fatty liver disease: results of a multicenter randomized clinical trial on efficacy and safety
The use of an original combination of ursodeoxycholic acid (UDCA) and glycyrrhizic acid (GA) as a component of pathogenetic therapy may enhance the effectiveness of treatment for nonalcoholic fatty liver disease (NAFLD) due to their complementary effects. Objective. To evaluate the efficacy, tolerability, and safety of a 12-week therapy for NAFLD with Phosphogliv URSO (capsules containing UDCA 250 mg and GA 35 mg) in comparison with UDCA monotherapy (Ursophalk, capsules 250 mg) and Phosphogliv (capsules containing phospholipids 65 mg and GA 35 mg). Material and methods. In a randomized, multicenter, comparative, open-label trial (n=225), the efficacy and safety of Phosphogliv URSO were assessed in patients with NAFLD over 12 weeks, compared with UDCA monotherapy and Phosphogliv. The primary endpoint was the change in aminotransferase level — alanine aminotransferase (ALT) and aspartate aminotransferase (AST). Results. The hypothesis of superiority of the UDCA+GA combination with respect to the primary endpoint was confirmed in the Phosphogliv URSO group (n=75). More than a twofold reduction in ALT and AST levels was achieved (to 37.6±20.5 U/L and 31.5±16.7 U/L, respectively), exceeding the reductions in the UDCA group by 57% for ALT and 78% for AST (p0.4), with the lowest incidence observed in the Phosphogliv group (p<0.05). Conclusion. GA, through its anti-inflammatory, antioxidant, and antifibrotic properties, enhances the therapeutic effect of UDCA. The synergistic action of GA in combination with UDCA or phospholipids on key pathogenetic mechanisms of NAFLD suggests that these regimens may represent a promising alternative to UDCA monotherapy.
- Open Access
- 26 March 2025
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 97 (2) , 137-144
Stage I cholelithiasis. Approaches to diagnosis and treatment. Results of the Machaon study
Aim. To review the results of the open observational study Makhaon on the use of a fixed combination of glycyrrhizic acid (GA) and ursodeoxycholic acid (UDCA) (Phosphogliv Urso) for the treatment of abdominal pain, assessment of contractile function of the gallbladder and bile rheology in patients with stage I cholelithiasis. Materials and methods. The study included 330 subjects, 44.5% males and 55.5% females. The study participants were 18–70 years old, with a mean age of 43.8±0.6 years. In 2021–2022, patients were treated in 14 clinical centers in 10 cities of the Russian Federation: Moscow, St. Petersburg, Stavropol, Volgograd, Perm, Samara, Ufa, Omsk, Novosibirsk, Tomsk. All patients received Phosphogliv Urso (UDCA 250 mg + sodium glycyrrhizinate 35 mg), 1 capsule 3 times daily with food for 6 months. Results. Based on the clear improvement, therapy with a combination of GA and UDCA has demonstrated high efficacy and safety and appears to be optimal for the treatment of abdominal pain, improvement of the contractile function of the gallbladder, and physicochemical properties of bile in patients with stage I cholelithiasis. Conclusion. Treating all variants of baseline changes in the bile rheology is an urgent task of modern biliology. Universal drugs for stage I cholelithiasis are UDCA and its fixed combination with GA.
- 26 March 2025
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 97 (2) , 137-144
Open AccessStage I cholelithiasis. Approaches to diagnosis and treatment. Results of the Machaon study
Aim. To review the results of the open observational study Makhaon on the use of a fixed combination of glycyrrhizic acid (GA) and ursodeoxycholic acid (UDCA) (Phosphogliv Urso) for the treatment of abdominal pain, assessment of contractile function of the gallbladder and bile rheology in patients with stage I cholelithiasis. Materials and methods. The study included 330 subjects, 44.5% males and 55.5% females. The study participants were 18–70 years old, with a mean age of 43.8±0.6 years. In 2021–2022, patients were treated in 14 clinical centers in 10 cities of the Russian Federation: Moscow, St. Petersburg, Stavropol, Volgograd, Perm, Samara, Ufa, Omsk, Novosibirsk, Tomsk. All patients received Phosphogliv Urso (UDCA 250 mg + sodium glycyrrhizinate 35 mg), 1 capsule 3 times daily with food for 6 months. Results. Based on the clear improvement, therapy with a combination of GA and UDCA has demonstrated high efficacy and safety and appears to be optimal for the treatment of abdominal pain, improvement of the contractile function of the gallbladder, and physicochemical properties of bile in patients with stage I cholelithiasis. Conclusion. Treating all variants of baseline changes in the bile rheology is an urgent task of modern biliology. Universal drugs for stage I cholelithiasis are UDCA and its fixed combination with GA.
- Open Access
- 21 August 2024
- Published by Russian Gastroenterolgocial Society in Russian Journal of Gastroenterology, Hepatology, Coloproctology
- Vol. 34 (3) , 115-134
Correction of Thrombocytopenia before Elective Surgery / Invasive Procedures in Patients with Liver Cirrhosis (Experts’ Agreement)
Introduction. As a result of portal hypertension (sequestration of platelets in an enlarged spleen) and liver failure (decreased production of thrombopoietin in the liver) in liver cirrhosis, thrombocytopenia develops, which is associated with the risk of periprocedural/perioperative bleeding complications. There are still unresolved questions regarding risk stratification of bleeding complications, the prognostic role of thrombocytopenia, as well as the need for treatment of thrombocytopenia and its methods.Materials and methods. The Russian Scientific Liver Society selected a panel of experts in the field of therapeutic and surgical hepatology, hematology, transfusion medicine to make reasoned statements and recommendations on the issue of treatment of thrombocytopenia before elective surgery / invasive procedures in patients with liver cirrhosis.Results. Relevant clinical issues were determined based on the PICO principle (patient or population, intervention, comparison, outcome). The Delphi panel made five questions and gave reasoned answers, framed as ‘clinical practice recommendations and statements’ with evidence-based comments. The questions and statements were based on the results of search and critical analysis of medical literature using keywords in English- and Russian-language databases. The formulated questions could be combined into four categories: bleeding risk stratification, the prognostic value of thrombocytopenia, the necessity and methods of thrombocytopenia drug correction, and bleeding risk reduction.Conclusions. The results of experts' work are directly related to high-quality management of patients with liver cirrhosis and thrombocytopenia, who have scheduled invasive procedures/surgery. Thus, this recommendations and statements can be used in clinical practice.
- 21 August 2024
- Published by Russian Gastroenterolgocial Society in Russian Journal of Gastroenterology, Hepatology, Coloproctology
- Vol. 34 (3) , 115-134
Open AccessCorrection of Thrombocytopenia before Elective Surgery / Invasive Procedures in Patients with Liver Cirrhosis (Experts’ Agreement)
Introduction. As a result of portal hypertension (sequestration of platelets in an enlarged spleen) and liver failure (decreased production of thrombopoietin in the liver) in liver cirrhosis, thrombocytopenia develops, which is associated with the risk of periprocedural/perioperative bleeding complications. There are still unresolved questions regarding risk stratification of bleeding complications, the prognostic role of thrombocytopenia, as well as the need for treatment of thrombocytopenia and its methods.Materials and methods. The Russian Scientific Liver Society selected a panel of experts in the field of therapeutic and surgical hepatology, hematology, transfusion medicine to make reasoned statements and recommendations on the issue of treatment of thrombocytopenia before elective surgery / invasive procedures in patients with liver cirrhosis.Results. Relevant clinical issues were determined based on the PICO principle (patient or population, intervention, comparison, outcome). The Delphi panel made five questions and gave reasoned answers, framed as ‘clinical practice recommendations and statements’ with evidence-based comments. The questions and statements were based on the results of search and critical analysis of medical literature using keywords in English- and Russian-language databases. The formulated questions could be combined into four categories: bleeding risk stratification, the prognostic value of thrombocytopenia, the necessity and methods of thrombocytopenia drug correction, and bleeding risk reduction.Conclusions. The results of experts' work are directly related to high-quality management of patients with liver cirrhosis and thrombocytopenia, who have scheduled invasive procedures/surgery. Thus, this recommendations and statements can be used in clinical practice.
- Open Access
- 16 January 2023
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 23,p. 142-147
The role of thrombocytopenia in the clinical management of patients with liver cirrhosis: opinion of experts in therapeutic and surgical hepatology
Seven of the country’s leading experts in the field of therapeutic and surgical hepatology answer questions on this issue: how relevant is thrombocytopenia in patients with CLD for clinical practice, what is the average proportion of patients who need correction of thrombocytopenia before scheduled and emergency surgical/invasive interventions and how is thrombocytopenia correction performed. All experts are unanimous in the opinion that thrombocytopenia is most common at the stage of cirrhosis. Further, the experts discussed the issues of the total number of patients with CLD, the proportion of patients with thrombocytopenia at all, the proportion of patients with thrombocytopenia in need of surgical interventions, the experts were asked to provide schemes for correcting thrombocytopenia, which they use in their clinical practice. The focus of the experts’ attention was on the discussion of patients who have a platelet level of less than 50 000/µl and need scheduled surgical interventions / invasive procedures. All experts unanimously stratify these interventions according to the risk of hemorrhagic complications: high – more than 1.5%, low – less than 1.5%. The most common and available method for the correction of thrombocytopenia at present is platelet transfusion. Details of all this information, as well as statistical data, can be found in this article.
- 16 January 2023
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 23,p. 142-147
Open AccessThe role of thrombocytopenia in the clinical management of patients with liver cirrhosis: opinion of experts in therapeutic and surgical hepatology
Seven of the country’s leading experts in the field of therapeutic and surgical hepatology answer questions on this issue: how relevant is thrombocytopenia in patients with CLD for clinical practice, what is the average proportion of patients who need correction of thrombocytopenia before scheduled and emergency surgical/invasive interventions and how is thrombocytopenia correction performed. All experts are unanimous in the opinion that thrombocytopenia is most common at the stage of cirrhosis. Further, the experts discussed the issues of the total number of patients with CLD, the proportion of patients with thrombocytopenia at all, the proportion of patients with thrombocytopenia in need of surgical interventions, the experts were asked to provide schemes for correcting thrombocytopenia, which they use in their clinical practice. The focus of the experts’ attention was on the discussion of patients who have a platelet level of less than 50 000/µl and need scheduled surgical interventions / invasive procedures. All experts unanimously stratify these interventions according to the risk of hemorrhagic complications: high – more than 1.5%, low – less than 1.5%. The most common and available method for the correction of thrombocytopenia at present is platelet transfusion. Details of all this information, as well as statistical data, can be found in this article.
- Open Access
- 5 October 2022
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 15,p. 70-82
Diagnosis of disorders in the coagulation system, assessment of the risk of hemorrhagic complications in severe cirrhosis/liver diseases according to global screening tests of the hemostasis system and principles for their correction: guidelines
Hemostasis disorders in cirrhosis / severe liver disease are complex, as they affect both pro- and anticoagulant factors, as well as pro- and antifibrinolytic components. Most of the tests that are used in clinical practice to assess coagulation do not take into account the compensatory capabilities of this system as a whole. This document provides guidance for the optimal application and interpretation of global screening tests in the assessment of hemostasis in cirrhosis/severe liver disease, analysis of risk factor of spontaneous and perioperative hemorrhagic complications in these patients, and possible ways to correct them. Thrombocytopenia is one of the most common hematological abnormalities in cirrhosis/ severe liver disease. The frequency of thrombocytopenia in such patients at the stage of liver cirrhosis is 70%, at the pre-cirrhotic stage – 6%. The latest scientific data on the use of thrombopoietin receptor agonists in chronic liver diseases are presented: which patients are the best candidates for a such of therapy. The rationality and limitations in prescribing blood components to patients with liver cirrhosis/severe liver diseases are described. Emphasis is placed on the fact that a number of hemorrhagic complications develop for other non-coagulopathic reasons: decompensated portal hypertension, traumatization of a varicose vein with trophic wall disorders, etc. Data are presented on the use of viscoelastic tests to optimize the management of patients with liver cirrhosis, which simultaneously assess the four main known components of the hemostasis system: the coagulation cascade, platelets, anticoagulant mechanisms and the fibrinolysis system. These tests allow optimization of transfusion of blood components in such patients and should be further studied. Research in this very complex area of hepatology is ongoing and must continue.
- 5 October 2022
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 15,p. 70-82
Open AccessDiagnosis of disorders in the coagulation system, assessment of the risk of hemorrhagic complications in severe cirrhosis/liver diseases according to global screening tests of the hemostasis system and principles for their correction: guidelines
Hemostasis disorders in cirrhosis / severe liver disease are complex, as they affect both pro- and anticoagulant factors, as well as pro- and antifibrinolytic components. Most of the tests that are used in clinical practice to assess coagulation do not take into account the compensatory capabilities of this system as a whole. This document provides guidance for the optimal application and interpretation of global screening tests in the assessment of hemostasis in cirrhosis/severe liver disease, analysis of risk factor of spontaneous and perioperative hemorrhagic complications in these patients, and possible ways to correct them. Thrombocytopenia is one of the most common hematological abnormalities in cirrhosis/ severe liver disease. The frequency of thrombocytopenia in such patients at the stage of liver cirrhosis is 70%, at the pre-cirrhotic stage – 6%. The latest scientific data on the use of thrombopoietin receptor agonists in chronic liver diseases are presented: which patients are the best candidates for a such of therapy. The rationality and limitations in prescribing blood components to patients with liver cirrhosis/severe liver diseases are described. Emphasis is placed on the fact that a number of hemorrhagic complications develop for other non-coagulopathic reasons: decompensated portal hypertension, traumatization of a varicose vein with trophic wall disorders, etc. Data are presented on the use of viscoelastic tests to optimize the management of patients with liver cirrhosis, which simultaneously assess the four main known components of the hemostasis system: the coagulation cascade, platelets, anticoagulant mechanisms and the fibrinolysis system. These tests allow optimization of transfusion of blood components in such patients and should be further studied. Research in this very complex area of hepatology is ongoing and must continue.
- Open Access
- 4 July 2022
- Published by SPb RAACI in Russian Journal of Infection and Immunity
- Vol. 12 (3) , 527-534
Urine excreted antibodies significance in the hemorrhagic fever with renal syndrome specific diagnosis
Relevance. Hemorrhagic fever with renal syndrome (HFRS) is an acute viral zoonosis. Being widespread in Eurasia, it holds a leading place in Russia among natural focal human diseases. The vast majority of HFRS cases in Russia, about 98%, are associated with Puumala virus. The disease is characterized by a wide range of clinical manifestations. Early specific diagnostics appears to be of a great importance for starting timely pathogenic therapy. The aim of the study was to clarify the diagnostic value of detecting hantavirus antibodies in the HFRS suspected patient urine. Materials and methods. Blood sera and urine samples from 68 patients at the Infectious Diseases Hospital in the city of Ufa, obtained with a 2-day interval, as well as urine and blood serum samples from 15 convalescents 1, 2, 3 and 6 months after disease onset were examined for hantavirus antibodies. 53 blood sera and urine samples from patients residing in Moscow, Moscow and Samara regions collected at different time points during the disease course were investigated in parallel. Antibodies were detected by the indirect immunofluorescence method. Results. On day 3, 4, 5 and 6 of disease, while specific antibodies were detected in the blood serum, antibodies in the urine were found in 85.7%, 89.4%, 93.1% and 100% of patients, respectively. The peak quantity of antibodies was excreted in the urine from days 5 to 11, which corresponds to the oliguric stage of the disease. In the convalescent period, antibodies were still detected in urine 1, 2 and 3 months afterwards in 86.7%, 46% and 20% of cases, respectively, but not detected 6 months later, which probably reflects the process of long-term restoration of the kidneys function. A moderate positive correlation between specific antibodies in serum and urine was observed only in the oliguric period of the disease. Conclusions. Detection of hantavirus antibodies simultaneously in blood serum and urine of febrile patients instead of paired blood sera allows to conduct HFRS diagnostics within the very first days of hospitalization and prevent severe complications due to timely pathogenic therapy.
- 4 July 2022
- Published by SPb RAACI in Russian Journal of Infection and Immunity
- Vol. 12 (3) , 527-534
Open AccessUrine excreted antibodies significance in the hemorrhagic fever with renal syndrome specific diagnosis
Relevance. Hemorrhagic fever with renal syndrome (HFRS) is an acute viral zoonosis. Being widespread in Eurasia, it holds a leading place in Russia among natural focal human diseases. The vast majority of HFRS cases in Russia, about 98%, are associated with Puumala virus. The disease is characterized by a wide range of clinical manifestations. Early specific diagnostics appears to be of a great importance for starting timely pathogenic therapy. The aim of the study was to clarify the diagnostic value of detecting hantavirus antibodies in the HFRS suspected patient urine. Materials and methods. Blood sera and urine samples from 68 patients at the Infectious Diseases Hospital in the city of Ufa, obtained with a 2-day interval, as well as urine and blood serum samples from 15 convalescents 1, 2, 3 and 6 months after disease onset were examined for hantavirus antibodies. 53 blood sera and urine samples from patients residing in Moscow, Moscow and Samara regions collected at different time points during the disease course were investigated in parallel. Antibodies were detected by the indirect immunofluorescence method. Results. On day 3, 4, 5 and 6 of disease, while specific antibodies were detected in the blood serum, antibodies in the urine were found in 85.7%, 89.4%, 93.1% and 100% of patients, respectively. The peak quantity of antibodies was excreted in the urine from days 5 to 11, which corresponds to the oliguric stage of the disease. In the convalescent period, antibodies were still detected in urine 1, 2 and 3 months afterwards in 86.7%, 46% and 20% of cases, respectively, but not detected 6 months later, which probably reflects the process of long-term restoration of the kidneys function. A moderate positive correlation between specific antibodies in serum and urine was observed only in the oliguric period of the disease. Conclusions. Detection of hantavirus antibodies simultaneously in blood serum and urine of febrile patients instead of paired blood sera allows to conduct HFRS diagnostics within the very first days of hospitalization and prevent severe complications due to timely pathogenic therapy.
- Open Access
- 15 December 2021
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 93 (12) , 1470-1476
The results of phase III multicenter open randomized controlled study REM-Chol-III-16 in patients with intrahepatic cholestasis syndrome caused by chronic diffuse liver diseases
Aim. To assess the safety and efficacy of Remaxol, solution for infusion, compared with parenteral form of S-adenosyl-L-methionine, in the treatment of patients with intrahepatic cholestasis syndrome accompanying chronic diffuse liver diseases of various etiology. Materials and methods. In a multicenter open-label comparative study of the safety and efficacy of Remaxol (inosine + meglumine + methionine + nicotinamide + succinic acid) 317 patients aged 18 to 65 years were randomized into 2 groups: patients of the experimental group (n=168) received intravenous Remaxol, solution for infusion, 400 ml, and patients of the control group (n=149) Heptral (S-adenosyl-L-methionine) 800 mg. The duration of treatment was 10 days. The primary efficacy endpoint was the proportion of patients who responded to therapy, as demonstrated by dynamics of laboratory parameters of liver functional status: decrease in gamma glutamyl transpeptidase level by 40%, and/or alkaline phosphatase level by 30%, and/or decrease total bilirubin level by 30% from baseline by the end of the treatment course. Results. The proportion of responders was 51% in the Remaxol group vs. 44.9% in the Heptral group (p=0.303); the lower limit of the one-sided 95% confidence interval for the difference in the proportions of responders was -4.01%, which exceeds the non-inferiority margin pre-defined by the study protocol, thus, the non-inferiority hypothesis was proven, i.e. Remaxol at a dose of 400 ml/day demonstrates similar efficacy to Heptral at a dose of 800 mg/day in patients with intrahepatic cholestasis syndrome associated with chronic diffuse liver diseases. Similar positive trends in the levels of transaminases, total bilirubin and the severity of pruritus were revealed in both treatment groups. We did not reveal statistically significant between-group differences in the frequency of adverse events definitely related to the study treatment. Conclusion. Administration of Remaxol as a part of the pathogenetic therapy of patients with intrahepatic cholestasis syndrome who need hepatoprotection is justified.
- 15 December 2021
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 93 (12) , 1470-1476
Open AccessThe results of phase III multicenter open randomized controlled study REM-Chol-III-16 in patients with intrahepatic cholestasis syndrome caused by chronic diffuse liver diseases
Aim. To assess the safety and efficacy of Remaxol, solution for infusion, compared with parenteral form of S-adenosyl-L-methionine, in the treatment of patients with intrahepatic cholestasis syndrome accompanying chronic diffuse liver diseases of various etiology. Materials and methods. In a multicenter open-label comparative study of the safety and efficacy of Remaxol (inosine + meglumine + methionine + nicotinamide + succinic acid) 317 patients aged 18 to 65 years were randomized into 2 groups: patients of the experimental group (n=168) received intravenous Remaxol, solution for infusion, 400 ml, and patients of the control group (n=149) Heptral (S-adenosyl-L-methionine) 800 mg. The duration of treatment was 10 days. The primary efficacy endpoint was the proportion of patients who responded to therapy, as demonstrated by dynamics of laboratory parameters of liver functional status: decrease in gamma glutamyl transpeptidase level by 40%, and/or alkaline phosphatase level by 30%, and/or decrease total bilirubin level by 30% from baseline by the end of the treatment course. Results. The proportion of responders was 51% in the Remaxol group vs. 44.9% in the Heptral group (p=0.303); the lower limit of the one-sided 95% confidence interval for the difference in the proportions of responders was -4.01%, which exceeds the non-inferiority margin pre-defined by the study protocol, thus, the non-inferiority hypothesis was proven, i.e. Remaxol at a dose of 400 ml/day demonstrates similar efficacy to Heptral at a dose of 800 mg/day in patients with intrahepatic cholestasis syndrome associated with chronic diffuse liver diseases. Similar positive trends in the levels of transaminases, total bilirubin and the severity of pruritus were revealed in both treatment groups. We did not reveal statistically significant between-group differences in the frequency of adverse events definitely related to the study treatment. Conclusion. Administration of Remaxol as a part of the pathogenetic therapy of patients with intrahepatic cholestasis syndrome who need hepatoprotection is justified.